Q1 REPORT 2015

sobi

Pioneer in Rare Diseases

We've got a story to tell

TABLE OF CONTENT

Financial Calendar

Annual General Meeting (AGM)	30 June 2015
Q2	17 July 2015
Q3	29 October 2015

CEO Statement

2015 is off to a solid beginning with excellent commercial performance across the portfolio as well as some successes in our development programmes. Total revenues were SEK 865 M, an increase of 39 per cent over the prior year in constant exchange rates, reflecting our strong underlying business. Cash flow increased compared to the same period last year and gross margin was in line with our expectations.

Continued growth across our business

ReFacto® delivered an unusually high result, reflecting a concentration of deliveries in the quarter. ReFacto continues to be an important contributor to Sobi's results.

Orfadin® showed continued growth, completing a full year following our initiation of direct sales in North America in April 2014. The outcome of this strategic move has impacted both patients and Sobi's results positively. In January 2015, we assumed rights for sales in South America following the termination of the last part of our prior distribution agreement in the Americas.

Kineret® also had a strong quarter, driven by volume growth across Europe and the US, which is especially pronounced in comparison to a low Q1 2014 due to wholesaler shifts. We continue to benefit from the widened paediatric indication for the product in both North America and Europe.

Our Partner Products business increased revenue, driven by continued growth for Kepivance and a one-time revenue milestone for Cometriq™. During the quarter we announced the restructuring of the Cometriq agreement with Exelixis, Inc., which has now been extended to 31 December 2019.

Finally we are pleased to see that the launch of Eloctate® and Alprolix® in partner Biogen's territories continued to gain momentum in the quarter, and we look forward to a possible approval later this year for Elocta® in the EU.

Important pipeline milestones

Looking at the pipeline, we had two important events in this period.

The positive results of the Kids B-LONG study in the quarter pave the way for European filing of Alprolix later this year and making an EU approval possible before the end of 2016. During the quarter we have continued to focus on building a world class haemophilia organisation to support the launch for the haemophilia products.

The EU Commission approved Xiapex® for the treatment of Peyronie's disease. We will now proceed with the launch of Xiapex for this indication and look forward to making this novel treatment available to patients across Europe.

I would like to thank our employees for their commitment, engagement, and achievements in the quarter. Their hard work genuinely makes a difference every day in the lives of patients and their families. I would also like to thank our shareholders for your interest and support for all we do here at Sobi.

Geoffrey McDonough
CEO and President

Solna, Sweden, 6 May 2015

Highlights Q1 2015

Business Highlights

- Extended and restructured distribution agreement with Exelixis for Cometriq
- Xiapex approved by the EU Commission for the treatment of Peyronie's disease
- Announced positive top-line efficacy and safety results from phase 3 Alprolix paediatric study (Kids B-LONG)

Financial Highlights

- Total revenue was SEK 865 M (573), an increase of 39 per cent at constant exchange rates
- Product revenue was SEK 633 M (406), an increase of 40 per cent at constant exchange rates
- Gross margin was 60 per cent (56)
- EBITA was SEK 172 M (-288)
- Ended the quarter with a cash position of SEK 682 M

Financial Highlights in USD[1]

- Total revenue was USD 104 M
- Product revenue was USD 76 M
- EBITA was USD 21 M
- Ended the quarter with a cash position of USD 82 M

[1]Exchange rate 1USD = 8.3365 SEK

Business Review Q1

Extended and restructured distribution agreement with Exelixis for Cometriq

The agreement with Exelixis, Inc. has been restructured and extended to 31 December 2019. Sobi is responsible for the commercialisation and distribution of Cometriq (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia and Turkey. The companies established the collaboration in February 2013, which was initially structured to expire 31 December 2015.

Xiapex approved by the EU Commission for the treatment of Peyronie's disease

The EU Commission approved Xiapex (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

Announced positive top-line efficacy and safety results from phase 3 Alprolix paediatric study

Together with partner Biogen, Sobi announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under age twelve with severe haemophilia B.

The successful completion of Kids B-LONG supports applications for paediatric indications in several geographies and is an important step in seeking marketing authorisation for Alprolix in Europe. The European Medicines Agency requires the inclusion of paediatric study data in the initial marketing application for a new haemophilia therapy.

Financial Review Q1

Key Therapeutic Areas

Revenue was SEK 431 M (241), an increase of 79 per cent. There was a positive exchange rate impact of approximately 22 per cent versus prior year.

Inflammation

Revenue for Kineret was SEK 198 M (124), an increase of 60 per cent. The increase was driven by positive volume growth across Europe, and higher US volumes compared to Q1 prior year which was unusually low due to wholesaler shifts.

Genetics & Metabolism

Revenue for Orfadin was SEK 180 M (76), an increase of 136 per cent versus prior year.

Sobi initiated direct sales in North America during the second quarter 2014, which impacted Q1 2014 negatively due to inventory buy-back from the previous distributor. This is the final quarter to reflect the impact on the run-rate for Orfadin resulting from this transaction. In January 2015, Sobi initiated direct sales also in South America following the termination of the distribution agreement with RDT for this territory.

Haemophilia

Revenue was SEK 17 M (11), an increase of 58 per cent versus prior year, representing royalties equal to 2 per cent from the sales of Eloctate and Alprolix in Biogen territories during the first quarter. Sobi received a milestone payment from Biogen last year of SEK 11 M.

Financial Summary

Amounts in SEK M	Q1 2015	Q1 2014	Change	Full year 2014
Total revenues	865	573	51%	2,607
Gross profit	519	320	62%	1,548
Gross margin	60%	56%		59%
EBITA[1]	172	-288	>100%	-43
EBITA excluding write-offs	172	37	>100%	307
EBIT (Operating profit/loss)	102	-358	>100%	-325
Profit/loss for the period	106	-329	>100%	-268

[1] FY 2014 includes write-offs relating to Kiobrina® of SEK 325 M in Q1 and to Multiferon® of SEK 25 M in 2014.

Partner Products

Revenue for Partner Products was SEK 202 M (165), an increase of 23 per cent versus prior year. The increase was driven by continued growth for Kepivance and a revenue milestone for Cometriq of SEK 18 M.

ReFacto

ReFacto manufacturing revenues and royalty were SEK 232 M (168), an increase of 38 per cent. The revenue reflects a concentration of deliveries in the quarter to Pfizer which is not expected to continue at this level in coming quarters. Manufacturing revenue was SEK 208 M (142). Royalty revenue was SEK 25 M (26).

Gross Profit

Gross profit for the first quarter was SEK 519 (320), equivalent to a gross margin of 60 per cent.

Operating Profit

Overall operating expenses excluding amortisations and write-downs were SEK 351 M (283).

Operating expenses for sales and administration excluding amortisations amounted to SEK 219 M (156). The increase reflects the full effect of FTEs hired in 2014 driven by the build-up of the Haemophilia organisation and geographic expansion. Q1 costs were impacted by unfavourable exchange rates of approximately 12 per cent compared to prior year.

Research and development costs excluding amortisation and write-downs were SEK 132 M (127).

The operating expenses were affected by costs relating to the long-term incentive programs of SEK 13 M. There is no cash flow impact from these programmes.

EBITA was SEK 172 M (-288), Q1 2014 included a one time write-off for Kiobrina of SEK 325 M.

Amortisations of Intangible assets amounted to SEK 71 M (70).

EBIT (operating profit) amounted to SEK 102 M (-358).

Net financial items and tax

Net financial items amounted SEK -1 M (-14), including exchange rate gains of SEK 14 M (0). Tax amounted to SEK 5 M (43).

Profit

Profit was SEK 106 M (-329).

Cash flow and investments

Cash flow from operations before change in working capital amounted to SEK 181 M (2).

Working capital impacted cash flow by SEK -12 M (133).

Cash flow from investing activities amounted to SEK -17 M (-6).

Cash

Cash position at quarter end was SEK 682 M, compared to SEK 519 M as of 31 December 2014.

Revenues by Business Line

Amounts in SEK M	Q1 2015	Q1 2014	Change %	Change % at CER[1]	Full year 2014
Key Therapeutic Areas					
Inflammation: Kineret	198	124	60%	37%	609
Genetics & Metabolism: Orfadin	180	76	136%	115%	548
Genetics & Metabolism: Other	36	31	18%	11%	118
Haemophilia: Royalties[2]	17	11	58%	19%	31
Total	**431**	**241**	**79%**	**57%**	**1,307**
Partner Products[3]	**202**	**165**	**23%**	**14%**	**682**
ReFacto					
Manufacturing revenues	208	142	46%	46%	466
Royalty revenues	25	26	-5%	-22%	152
Total	**232**	**168**	**38%**	**36%**	**618**
Total revenues	**865**	**573**	**51%**	**39%**	**2,607**

[1] Constant Exchange Rate.

[2] Royalties on commercial sales, Biogen. Note that Q1 2014 includes a one-time milestone payment.

[3] Includes a one-time revenue milestone for Cometriq.

Net Debt

Sobi ended the quarter with a net debt of SEK 136 M, compared to SEK 298 M as of 31 December 2014.

Equity

Consolidated shareholders' equity as of 31 of March 2015 amounted to SEK 4,645 M compared to 4,523 M as of 31 December 2014.

Parent Company

Net sales in Q1 2015 for the Parent Company, Swedish Orphan Biovitrum AB (publ), amounted to SEK 724 M (626) of which SEK 256 M (293) referred to sales to Group companies. Income after financial items amounted to SEK 179 M (-96). Investments in tangible and intangible assets amounted to SEK 16 M (5).

Outlook 2015 - EBITA expectations clarified

For 2015, Sobi expects total revenues for the full year to be in the range of SEK 2,800 to 3,000 M, and gross margin to be in the range of 58-60 percent.

Operating costs are projected to increase as the company continues to prepare for the planned launch of Elocta. Sobi expects EBITA to be in the range of SEK 300-400 M.[1] The outlook for 2015 is based on constant exchange rates as of 19 February 2015, and excludes revenue from the potential European launch of Elocta.

Operating Profit/Loss

Amounts in SEK M	Q1 2015	Q1 2014	Full year 2014
Total revenues	865	573	2,607
Total cost of goods and services sold	-346	-254	-1,059
Gross profit	**519**	**320**	**1,548**
Gross Margin	*60%*	*56%*	*59%*
Sales and administration expenses less amortisations and write-downs	-219	-156	-750
Research and development expenses less amortisations and write-downs	-132	-127	-501
Total opex less amortisations and write-downs	**-351**	**-283**	**-1,250**
Other operating revenues/expenses	**4**	**-325**	**-341**
EBITA	**172**	**-288**	**-43**
Amortisations and write-downs relating to			
Sales and administration expenses	-71	-70	-282
Amortisations and write-downs	**-71**	**-70**	**-282**
EBIT	**102**	**-358**	**-325**

The statement is a non-IFRS statement. For IFRS purpose please see Group Income Statement.

[1]The original outlook presented on 19 February 2015 stated that "Sobi expects EBITA to be in line with the adjusted 2014 level."

Other Information

Personnel

As of March 2015, the number of full-time equivalents in personnel was 621 (584, December 2014).

Significant events after the period

Received orphan drug designation for Elocta in Switzerland
The company received orphan drug designation in Switzerland for its long acting haemophilia drug candidate Elocta (rFVIIIFc) developed for the treatment of haemophilia A. An orphan drug designation is to encourage the development of medicines for rare diseases and provides orphan status to drugs and biologics under development.

Statement regarding recent speculation
The Board confirms that it has received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. There can be no certainty that an offer will be made, nor as to the terms of any such offer. A further announcement will be made when appropriate.

Sobi´s Board of Directors postpones AGM
In light of the proposal the Board of Sobi decided to postpone the 2015 Annual General Meeting of Shareholders (AGM), scheduled for 6 May 2015, to 30 June 2015 in order to be able to provide as much clarity as possible by the time of the meeting. A separate notification regarding the AGM date will be published in due course.

CHMP adopts positive opinion for the Orfadin oral suspension formulation and the 20 mg capsule for the treatment of HT-1
The company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for the oral suspension formulation and the 20 mg capsule of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1).

This report has not been reviewed by the company's auditors.

Geoffrey McDonough
CEO and President

Solna, Sweden, 6 May 2015

Forward-looking statement
This report includes forward-looking statements. Actual results may differ from those stated. Internal factors such as the successful management of research programmes and intellectual property rights may affect future results. There are also external conditions such as the economic climate, political changes and competing research programmes that may affect Sobi's results.

Financial Statements

Group

Statement of Comprehensive Income

Amounts in SEK M	Q1 2015	Q1 2014	Full year 2014
Total revenues	865	573	2,607
Total cost of goods and services sold	-346	-254	-1,059
Gross profit	**519**	**320**	**1,548**
Sales and administration expenses	-289	-226	-1,032
Research and development expenses	-132	-127	-501
Other operating revenues/expenses	4	-325	-341
Operating profit/loss	**102**	**-358**	**-325**
Financial income/expenses	-1	-14	6
Income tax benefit/expense	5	43	51
Profit/loss for the period	**106**	**-329**	**-268**
All earnings are attributable to parent company shareholders			
Other comprehensive income			
Items that will not be reclassified to profit/loss			
Remeasurements of post employment benefit obligations	–	–	1
Items that may be reclassified subsequently to profit/loss			
Translation difference	0	–	4
Cash flow hedge (net of tax)	2	-1	1
Comprehensive income for the period	**108**	**-329**	**-263**
Amortisation and write-down of intangible assets included in Sales and administration expenses	-71	-70	-282
Earning/loss per share before and after dilution	0.40	-1.22	-1.01

Group
Balance sheet

Amounts in SEK M	Mar 2015	Dec 2014	Sep 2014	Jun 2014	Mar 2014
ASSETS					
Non-current assets					
Intangible fixed assets [1]	4,192	4,248	4,231	4,241	4,303
Tangible fixed assets	110	115	116	118	120
Financial fixed assets	79	73	67	43	39
Total non-current assets	**4,380**	**4,436**	**4,414**	**4,402**	**4,462**
Current assets					
Inventories	765	764	726	729	678
Accounts receivable	647	480	451	448	377
Current receivables, non-interest bearing	133	172	169	164	133
Cash and cash equivalents	682	519	611	503	574
Total current assets	**2,226**	**1,935**	**1,957**	**1,844**	**1,762**
Total assets	**6,606**	**6,371**	**6,371**	**6,246**	**6,224**
EQUITY AND LIABILITIES					
Shareholders´ equity	**4,645**	**4,523**	**4,533**	**4,475**	**4,443**
Long-term liabilities					
Long-term debt	817	816	815	815	794
Long-term liabilities, non-interest bearing	282	285	292	270	274
Total long-term liabilities	**1,099**	**1,101**	**1,108**	**1,085**	**1,068**
Current liabilities					
Short term debt	2	2	2	2	2
Current liabilities, non-interest bearing	861	745	729	684	711
Total short-term liabilities	**862**	**747**	**730**	**686**	**713**
Total equity and liabilities	**6,606**	**6,371**	**6,371**	**6,246**	**6,224**

[1] Including goodwill SEK 1,554 M, as per 31 March 2015

Group
Changes in Equity

Amounts in SEK M	Jan - Mar 2015	Jan - Mar 2014	Full year 2014
Opening balance	**4,523**	**4,769**	**4,769**
Sharebased compensation to employees	5	3	16
Transfer of own shares	10	–	–
Comprehensive income for the period	108	-329	-263
Equity, end of period	**4,645**	**4,443**	**4,523**

Group
Cash Flow Statement

Amounts in SEK M	Q1 2015	Q1 2014	Full year 2014
Net result	106	-329	-268
Non-cash items[1]	75	331	567
Cash flow from operations before change in working capital	**181**	**2**	**299**
Change in working capital	-12	133	-66
Cash flow from operations	**169**	**135**	**234**
Investment in intangible fixed assets	-15	-4	-160
Investment in tangible fixed assets	-2	-2	-23
Cash flow from investing activities	**-17**	**-6**	**-184**
Loans - Raising/Amortization	–	–	20
Transfer of own shares	10	–	–
Cash flow from financing activities	**10**	**–**	**20**
Net change in cash	**163**	**129**	**70**
Liquid funds at the beginning of the period	519	445	445
Translation difference in cash flow and liquid funds	0	–	4
Liquid funds at the end of the period	**682**	**574**	**519**
[1] **Depreciations, amortization, deferred tax and other:**			
Depreciation tangible fixed assets	8	8	32
Amortization intangible assets	71	70	282
Deferred tax	-8	-45	-71
Other, whereof Kiobrina write-off amounts to SEK 268 M in 2014.	5	298	325

Group

Key Ratios and Other Information

Amounts in SEK M	Q1 2015	Q1 2014	Full year 2014
Profit numbers			
Gross profit	519	320	1,548
EBITDA	180	-280	-12
EBITA	172	-288	-43
EBIT	102	-358	-325
Profit/loss	106	-329	-268
Per share data (SEK)			
Earning/loss per share	0.40	-1.22	-1.01
Earning/loss per share after dilution	0.40	-1.22	-1.01
Shareholders' equity per share	17.2	16.4	16.7
Shareholders' equity per share after dilution	17.2	16.4	16.7
Other information			
Gross margin	60%	56%	59%
Equity ratio	70%	71%	71%
Net debt	136	222	298

Parent Company

Statement of Comprehensive Income

Amounts in SEK M	Q1 2015	Q1 2014	Full year 2014
Total revenues	724	626	2,328
Total cost of goods and services sold	-282	-241	-974
Gross profit	**442**	**385**	**1,355**
Sales and Administration expenses	-145	-125	-624
Research and Development expenses	-125	-118	-470
Other operating revenues/expenses	1	-55	-64
Operating profit/loss	**173**	**87**	**197**
Result from participation in Group companies[1]	–	-177	-175
Financial income/expenses	6	-6	37
Profit/loss after financial items	**179**	**-96**	**59**
Group contribution	–	–	-159
Income tax benefit/expenses	-6	-17	-21
Profit/loss for the period	**173**	**-113**	**-121**
Other comprehensive income			
Items that may be reclassified subsequently to profit/loss			
Cash flow hedge (net of tax)	2	-1	1
Comprehensive income for the period	**175**	**-114**	**-120**
Amortization and write-down of intangible assets included in Sales & Adm expenses	-22	-22	-89

[1] 2014 includes write-down in value of ownership of Arexis relating to Kiobrina, of SEK 177 M

Parent Company
Balance Sheet

Amounts in SEK M	Mar 2015	Dec 2014	Sep 2014	Jun 2014	Mar 2014
ASSETS					
Non-current assets					
Intangible fixed assets	999	1,007	942	903	917
Tangible fixed assets	99	104	106	108	109
Financial fixed assets	3,914	3,919	3,918	3,918	3,916
Total non-current assets	**5,012**	**5,029**	**4,966**	**4,929**	**4,943**
Current assets					
Inventories	708	680	656	656	612
Current receivables, non-interest bearing	1,113	1,038	1,166	1,210	1,121
Cash and cash equivalents	578	392	517	432	513
Total current assets	**2,399**	**2,111**	**2,340**	**2,298**	**2,246**
Total assets	**7,411**	**7,140**	**7,306**	**7,226**	**7,189**
EQUITY AND LIABILITIES					
Shareholders´ equity	***5,700***	***5,510***	***5,665***	***5,580***	***5,511***
Long-term liabilities					
Long-term debt	813	812	811	810	789
Total long-term liabilities	**813**	**812**	**811**	**810**	**789**
Current liabilities					
Current liabilities, non-interest bearing	898	818	830	836	888
Total short-term liabilities	**898**	**818**	**830**	**836**	**888**
Total equity and liabilities	**7,411**	**7,140**	**7,306**	**7,226**	**7,189**

Parent Company
Change in Shareholders´ Equity

Amounts in SEK M	Jan-Mar 2015	Jan-Mar 2014	Full Year 2014
Opening balance	**5,510**	**5,622**	**5,622**
Sharebased compensation to employees	5	3	9
Transfer of shares	10	–	–
Comprehensive income for the period	175	-114	-120
Equity, end of period	**5,700**	**5,511**	**5,510**

Financial Notes

Note 1 – Accounting and valuation principles and other information

Important accounting principles

This interim report has been prepared in accordance with IAS 34 and with the Annual Accounts Act. The consolidated financial statements for the period January—March 2015 have been prepared in accordance with the Financial Reporting Standards (IFRS) and IFRIC interpretations as adopted by the EU and the Swedish Annual Act. The parent company applies the Annual Accounts Act and Council for Financial Reporting, RFR 2 Reporting for legal entities. The consolidated financial statements have been prepared according to the historical cost convention, except in the case of financial assets and financial assets and liabilities (including derivative instruments) which are measured at fair value through profit and loss.

Accounting principles applied, except for the changes listed below, are in accordance with those described in the 2014 Annual Report. More detailed information about the Group's accounting and valuation principles can be found in the 2014 Annual Report which is available on www.sobi.com.

Change in accounting principles

From fiscal year 2015 comes a number of new and revised standards in force. These standards have had no material impact on the consolidated financial statements.

Operating risks

All business operations involve risk. Managed risk-taking is necessary to maintain good profitability. Risk may be due to events in the external environment and may affect a certain industry or market. Risk may also be specific to a certain company.

Sobi is exposed to three main risk categories:

- Operational risks, e.g. due to the capital-intensive and risky nature of new drug development, dependence on external partners in various collaborations, product liability claims and laws and rules on the treatment of hazardous materials.
- External risks such as patent infringements, competition within product concepts and decisions by authorities regarding product use and prices.
- Financial risks, such as currency risk, interest risk, credit risk and liquidity risk.

A more detailed description of the Group's risk exposure and risk management is included in Sobi's 2014 Annual Report (see the Directors' Report). There are no major changes in the Group's risk exposure and risk management in 2015.

Note 2 – Fair values of financial instruments

The group carries derivatives. Refer to the annual report 2014 for a narrative description of the purpose of the holdings. The derivatives (under the heading "current liabilities") are all level 2 instruments in the fair value hierarchy in the standard IFRS 13 (inputs other than quoted prices that are observable for the instruments, either directly or indirectly, are used in the fair value measurement). All derivatives are measured at fair value based on market data in accordance with IFRS. At 31 March 2015 the reported value in the balance sheet for the derivatives was SEK -9 M (-7). As of 31 March 2015 all other financial instruments in the balance sheet, with the exception of the group's bond, have reported values that are in all material aspects equivalent to fair value. At 31 March 2015 the reported value in the balance sheet for the bond was SEK 793 M (789). Fair value of the bond is deemed to be SEK 832 M (854). The fair value is based on the average of the bid-ask-spread at the balance sheet date.

Note 3 – Contractual commitments for the acquisition of intangible assets

In October 2014, Sobi's partner Biogen submitted an MAA for Elocta (rFVIIIFc) to the EMA. This application for marketing approval to the EMA, together with the delivery of data from Biogen to Sobi, triggered Sobi's exclusive opt-in right to assume final development and commercialisation of Elocta in Europe, North Africa, Russia and most countries in the Middle East. On November 21, Sobi exercised its opt-in right and paid, in accordance with the agreement, a deposit of USD 10 M. The deposit has been recognised in the balance sheet as an advance payment under intangible fixed assets.
Following the EU regulatory approval of Elocta, Sobi will be liable to reimburse Biogen for 50 per cent of the total production costs for clinical manufacture of the product, development costs for the product from 1 October 2009 until the date on which Sobi is registered as the Marketing Authorisation Holder, or 90 days after the approval, and certain shared expenses related to regulatory approval, costs for final development and commercialisation, and 100 per cent of some development costs that only benefitted Sobi's territory. Total payment is estimated to be about USD 245 M.

Definitions and Glossary

Definitions

Capital employed
Total assets less non-interest-bearing responsibilities.

Cash flow per share
Changes in cash and cash equivalents divided by the weighted average number of outstanding shares.

Debt/Equity ratio
Relative proportion of shareholders equity and debt used to finance the company's assets.

EBIT
Earnings Before Interest and Taxes (Operating profit/loss).

EBITA
Operating profit/loss before amortisation.

EBITDA
Operating profit/loss before depreciation and amortisation.

Earnings per share
The portion of a company´s profit allocated to each outstanding share of common stock.

Equity per share
The value of the company´s common stock adjusted for any outflow (dividends and stock buy backs) and inflow (retained earnings) related to amount of shares outstanding.

Equity ratio
Shareholders' equity as a proportion of total assets.

Full-time equivalents
Unit that indicates the workload of an employed person in a way that makes workloads comparable across various contexts.

Gross margin
Gross profit as a percentage of sales.

Gross profit
Net sales less cost of goods and services sold.

Net debt
Interest bearing long term and short term debt less cash at bank.

Non-recurring items
Non-recurring items are defined as transactions of a nonrecurring nature.

Profit/loss
Profit/loss for the period.

Return on shareholders' equity
Profit/loss after tax as a percentage of average shareholders' equity.

Return on capital employed
Earnings Before Interest and Tax (EBIT)/Capital Employed.

Return on equity
Profit/loss after tax as a percentage of average shareholders' equity.

Return on total capital
Profit/loss after financial items plus financial expenses as a percentage of average total assets.

Shareholders' equity per share
Shareholders' equity divided by the number of shares.

Glossary

Alprolix (rFIXFc)
rFIXFc is a long-acting recombinant factor IX Fc fusion protein product candidate for people with haemophilia B. rFIXFc is also known as Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein], in the US, Canada, Australia and Japan, where it is approved for the treatment of haemophilia B.

Cometriq
Cometriq (cabozantinib) is a therapy for the treatment of adult patients with progressive, unresectable, locally advanced or metastatic medullary thyroid carcinoma (MTC).

Elocta (rFVIIIFc)
Elocta is a long-acting recombinant factor VIII Fc fusion protein product candidate in the EU for people with haemophilia A. Elocta is the trade name in Europe for rFVIIIFc, also known as Eloctate [Antihemophilic Factor VIII (Recombinant), Fc Fusion Protein] in the US, Canada, Australia and Japan, where it is approved for the treatment of haemophilia A. A MAA for Elocta is currently under review by the EMA.

EMA
European Medicines Agency.

EMENAR
A business region including Europe, Middle East, North Africa and Russia.

Haemophilia
Haemophilia is a group of hereditary genetic disorders that impair the body's ability to control blood clotting or coagulation. Haemophilia A (clotting factor VIII deficiency) is the most common form of the disorder, present in about 1 in 5,000 male births. Haemophilia B (clotting factor IX deficiency) occurs in around 1 in about 25,000 male births.

Kepivance
A therapy indicated to decrease the incidence and duration of severe oral mucositis in patients with haematologic malignancies receiving myelotoxic therapy requiring haematopoietic stem cell support.

Kineret
Kineret (anakinra) is a recombinant protein drug which blocks the biological activity of IL-1 by binding to the interleukin-1 (IL-1) type 1 receptor, which is expressed in a wide variety of tissues and organs. IL-1 is a key mediator of inflammation and driver of autoinflammatory diseases in both adults and children.

MAA
Marketing Authorisation Application.

Orfadin
Orfadin (nitisinone) is a pharmaceutical used for the treatment of Hereditary Tyrosinaemia type 1 (HT-1), a rare genetic disorder which can cause liver failure, kidney dysfunction and neurological problems.

Peyronie's disease
Peyronie's disease is a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis. The scar tissue, known as a Peyronie's plaque, may harden and reduce flexibility, which may cause bending or arching of the penis during erection. Peyronie's disease can result in varying degrees of penile curvature deformity and disease "bother" (encompassing concern about erection appearance, erection pain and the impact of Peyronie's disease on intercourse and on frequency of intercourse).

Xiapex
Xiapex (collagenase clostridium histolyticum), is a pharmacological treatment for Dupuytren's contracture and Peyronie's disease and may be an alternative to invasive and often complicated surgery for patients.

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm, Sweden
Visiting address: Tomtebodavägen 23 A
Telephone: +46 8-697 20 00
Fax: +46 8-697 23 30
www.sobi.com

About Sobi

Sobi is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primary focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products for partner companies across Europe, Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com